品牌簡介

Ethos Biosciences-Exocell offers Nephrology assay expertise to advance the understanding and treatment of diabetes A leader in research on diabetes, endocrinology, and metabolism, Margo Cohen founded Exocell in 1988 to develop diabetes-related diagnostic products, and subsequently established Glycadia to develop therapeutic products. Under her leadership, Exocell quickly became a leader in nephrology diagnostics with 15 patents and over 2000 research citations. Now a part of Ethos Biosciences (which is a part of Ott Scientific), Exocell products continue to serve the top academic, biotech, and pharma research teams across the globe. Why choose Exocell Assays from Ethos Biosciences? From the original Albuwell ELISA and Creatinine Companion Kits, which have become the gold standard assays for microalbuminuria measurement, the analyte list has expanded to include biomarkers for other conditions that frequently co-occur with diabetes. Regardless of the analyte, each kit embodies our commitment to accurate and precise measurement, with reagents and assays designed to maximize quality and ease-of-use while minimizing variability.